AIMS: Riluzole is used in a fixed dosing schedule of 50 mg twice daily to treat patients with amyotropic lateral sclerosis (ALS), one form of motor neurone disease. The large variability in the pharmacokinetics of riluzole may be a factor contributing to its limited therapeutic benefit. Riluzole is assumed to be mainly metabolized by the cytochrome P450 enzyme 1A2 (CYP1A2). The aim of the study was to investigate the relationship between CYP1A2 activity and riluzole clearance with a view to optimize drug treatment. METHODS: A group of 30 ALS patients participated in the study. In each patient the CYP1A2 activity was determined using caffeine as a metabolic probe. Riluzole clearance was estimated from serum drug concentration measurements followed by Bayesian fitting. RESULTS: Riluzole clearance and the serum paraxanthine : caffeine (P/C) ratio showed a positive correlation (r = 0.693; P = 0.0002). Linear regression analysis identified the P/C ratio (beta: 1.16) and height (beta: 0.027) as independent predictors of riluzole clearance (adjusted r2 = 0.369). CONCLUSIONS: The P/C ratio, used as measure of CYP1A2 activity, significantly correlated with the riluzole clearance, although only 37% of the observed variability could be explained.
AIMS: Riluzole is used in a fixed dosing schedule of 50 mg twice daily to treat patients with amyotropic lateral sclerosis (ALS), one form of motor neurone disease. The large variability in the pharmacokinetics of riluzole may be a factor contributing to its limited therapeutic benefit. Riluzole is assumed to be mainly metabolized by the cytochrome P450 enzyme 1A2 (CYP1A2). The aim of the study was to investigate the relationship between CYP1A2 activity and riluzole clearance with a view to optimize drug treatment. METHODS: A group of 30 ALSpatients participated in the study. In each patient the CYP1A2 activity was determined using caffeine as a metabolic probe. Riluzole clearance was estimated from serum drug concentration measurements followed by Bayesian fitting. RESULTS:Riluzole clearance and the serum paraxanthine : caffeine (P/C) ratio showed a positive correlation (r = 0.693; P = 0.0002). Linear regression analysis identified the P/C ratio (beta: 1.16) and height (beta: 0.027) as independent predictors of riluzole clearance (adjusted r2 = 0.369). CONCLUSIONS: The P/C ratio, used as measure of CYP1A2 activity, significantly correlated with the riluzole clearance, although only 37% of the observed variability could be explained.
Authors: G J Groeneveld; H J van Kan; J S Toraño; J H Veldink; H J Guchelaar; J H Wokke; L H van den Berg Journal: J Neurol Sci Date: 2001-10-15 Impact factor: 3.181
Authors: H J M van Kan; M Spieksma; G J Groeneveld; J Sastre Toraño; L H van den Berg; H J Guchelaar Journal: Biomed Chromatogr Date: 2004-11 Impact factor: 1.902
Authors: A Le Liboux; P Lefebvre; Y Le Roux; P Truffinet; M Aubeneau; S Kirkesseli; G Montay Journal: J Clin Pharmacol Date: 1997-09 Impact factor: 3.126
Authors: L Lacomblez; G Bensimon; P N Leigh; P Guillet; L Powe; S Durrleman; J C Delumeau; V Meininger Journal: Neurology Date: 1996-12 Impact factor: 9.910
Authors: Mark E McDonnell; Matthew D Vera; Benjamin E Blass; Jeffrey C Pelletier; Richard C King; Carmen Fernandez-Metzler; Garry R Smith; Jay Wrobel; Suzie Chen; Brian A Wall; Allen B Reitz Journal: Bioorg Med Chem Date: 2012-07-21 Impact factor: 3.641
Authors: Jeffrey C Pelletier; Suzie Chen; Haiyan Bian; Raj Shah; Garry R Smith; Jay E Wrobel; Allen B Reitz Journal: ACS Med Chem Lett Date: 2018-06-15 Impact factor: 4.345